Dr. Mahajan’s lab provides an immersive, intensive training environment for students and fellows to discover the molecular mechanisms that cause blindness and develop therapies to prevent vision loss. Highly collaborative research teams are made up of scientists, surgeons, and engineers from around the world, interacting on a daily basis and using advanced scientific methods.
Paul joined the Mahajan Lab as a postdoctoral research fellow and member of the ChEM-H Medicinal Chemistry Knowledge Center in 2018. He completed his Ph.D. in Organic Chemistry from Temple University in 2015 and in 2016 continued his studies at the California Institute of Technology. Paul was awarded an NIH Postdoctoral Fellowship in 2017 to pursue small molecule inhibitors of DNA-protein binding. Paul is currently developing small molecule protease inhibitors for the treatment of Autosomal Dominant Neovascular Inflammatory Vitreoretinal (ADNIV). His research interests include the development of chemical tools and therapeutics for the study of aberrant cellular signaling in muscular and neurological disease.
Katie is currently a post-doctoral fellow. She earned a Master of Science in Human Clinical Nutrition from Columbia University in 2009 and a Ph.D. in Nutrition and Metabolic Biology from Columbia University in 2013. She completed a post-doctoral fellowship in genome engineering, stem cell, and developmental biology at the Whitehead Institute for Biomedical Research. Her overall research goal is to discover and understand the mechanisms underlying neuroretinal disease and to develop novel therapeutics for these complex degenerative disorders using gene therapy, cell transplantations, and genome engineering technologies. She utilizes gene editing strategies to create mouse models for human disease and studies specific mutations within human embryonic and induced pluripotent stem cells.